At least eight profitable biotechs and pharmas are slated to report earnings this week. Nearly all are expected to post positive EPS growth, including a 45% increase by Celgene Corp. (NASDAQ:CELG). Celgene markets Revlimid lenalidomide for multiple myeloma (MM